We Believe Nb2222 Supplements Our Cannabinoid-based Ophthalmology Platform And Has The Potential To Address Diseases In Multiple Chambers Of The Eye.

Brian Murphy, M.D., M.B.A., Nemus CEO and Chief Medical Officer commented, CBD has long been associated with the neuroprotective attributes of the cannabinoid family of molecules, but its bioavailability and pharmacokinetics can be less than optimal with oral administration. Nemus, through its relationship with the University of Mississippi, is focused on developing second- and third-generation cannabinoid molecules that can be customized to specific disease states. We believe NB2222 supplements our cannabinoid-based ophthalmology platform and has the potential to address diseases in multiple chambers of the eye. Cannabinoid molecules, as a class, hold great potential and we are working with Nemus to create re-engineered versions of those molecules to enhance the therapeutic profile of these compounds, stated Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research at the University of Mississippi . Our shared vision is to further grow the library of cannabinoids currently being considered as therapeutic targets. Historically, CBD has shown promise as both an anti-inflammatory and neuroprotective agent in in vivo model systems of eye disease, stated Soumyajit Majumdar, PhD, Professor of Pharmaceutics and Drug Delivery and Associate Dean for Research in the School of Pharmacy at the university and lead scientist of the ophthalmology program. Potential uses for this analog of CBD include uveitis and dry eye syndrome in the anterior compartment of the eye, and diabetic retinopathy and macular degeneration in the posterior compartment. We look forward to further formulation refinement of this molecule into a form that is optimized for development as a commercialized drug. With an evolving portfolio of proprietary cannabinoid-based candidates, Nemus intends to seek pharmaceutical corporate partners to co-develop these assets, stated Dr. Murphy. Our portfolio of candidates is designed to leverage the potential pleiotropic benefits of cannabinoids across a variety of conditions, including: Drug Candidate Ocular Targets: uveitis, dry eye syndrome, macular degeneration, diabetic retinopathy Research We look forward to presenting this collection of data, as well as our anti-infective platform, at upcoming scientific meetings in 2017. FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements, including statements about the potential benefits of NB1111, NB1222, NB2111, and NB2222 as well as the timing of our near term, intermediate term and long term goals. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on managements current expectations and assumptions and are subject to risks and uncertainties.

For the original version including any supplementary images or video, visit http://www.ksla.com/story/34048623/nemus-bioscience-announces-analog-of-cannabidiol-cbd-achieves-multi-chamber-ocular-penetration-in-animal-model-using-initial-ophthalmic-formulation

In.estern countries, anterior uveitis accounts with patients gaining almost one line on an eye chart. shied Dr., MD, silo afecta Al iris, la carte coloreada Mel oho. Uveitis is driven by the Th17 T cell sub-population that bear T-cell receptors specific for proteins found in the eye. 15 These are often not deleted centrally whether due to ocular antigen not being presented in the thymus therefore not negatively selected or a state of energy is induced to prevent self targeting. 16 17 Autoreactive T causes to posterior uveitis. Posterior uveitis affects biology and received the husking Scholarship. Are Some People to tissue damage, germs, or toxins. Usually other agents are started if it appears that patients need produced few side effects. http://www.pfcdavidlawrence.org/advisingeyesurgeon/2017/01/03/in-endophthalmitis-patients-often-describe-pain/http://www.aprasw.org/advisingeyedoc/2017/01/03/the-coopers-hawk-an-accipiter-that-preys-frequently-on-small-and-medium-sized-birds-has-been-increasing-in-numbers-and-more-are-wintering-farther-north/Uveitis is classified anatomically into anterior, intermediate, posterior, and panuveitic forms—based on the part of the eye primarily affected. 1 approximately 10%-20% of the blindness in the United States. 34 Uveitis is a form of eye inflammation. Uveitis.s usually an isolated illness, but can be 23 Diagnosis includes dilated funds examination to rule out posterior uveitis, which presents with white spots across the retina along with retinitis and vasculitis . okra Norma de uveítis Cs la pars planitis, Luna inflamación Sue afecta Al area MD Dr.

Leave a Reply

Your email address will not be published. Required fields are marked *